RecruitingEarly Phase 1NCT06787066
Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms
Sponsor
University of Missouri-Columbia
Enrollment
75 participants
Start Date
Jul 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 70 Years
Inclusion Criteria3
- Assigned female at birth
- -70 years of age
- Body mass index (BMI) <30 kg/m2
Exclusion Criteria12
- Assigned male at birth
- Pregnancy, breastfeeding
- Body mass index ≥30 kg/m2
- Oral hormonal contraception in last 6 months, history of hormone replacement therapy, oophorectomy
- Current smoking/nicotine use
- Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
- Nerve/neurologic disease
- Cardiovascular, hepatic, renal, respiratory disease
- Blood pressure ≥140/90 mmHg
- Diabetes, Polycystic ovarian syndrome
- Communication barriers
- Prescription medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPropranolol Hydrochloride
Examine how IV propranolol impacts sympathetic transduction
DRUGPhentolamine Injection
Examine how IV phentolamine impacts sympathetic transduction
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06787066
Related Trials
Menopausal HT for Women Living With HIV (HoT)
NCT0685617423 locations
Brazilian Registry of Menopausal Health
NCT070056481 location
Menopause Transition, Sex Hormone Deficiency and Autonomic and Vascular Function
NCT064901461 location
Multimodal Program for Climacteric Women
NCT064199722 locations
Avatar-Based Education and Counseling for Spousal Support During Menopause
NCT075993191 location